Evidence map›Paper›PMID 36568831›Full record

ReviewThe Yale journal of biology and medicine2022

The Intriguing Carbapenemases of

Dalal Hammoudi Halat, Carole Ayoub Moubareck

Open access · greenAbstract readReview
In one paragraph

Review in The Yale journal of biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Multidrug-resistant Pseudomonas aeruginosa in ICU patients and hospital surfaces: β-lactamase burden, biofilm formation and clonal spread.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Genomic Insights into Carbapenem-ResistantJournal of clinical medicine · 2026
    Article
  7. Article
  8. Article
  9. Whole-genome sequencing reveals molecular characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026
    Article
  10. Antibiotic resistance inFrontiers in microbiology · 2026
    Review
  11. Article
  12. Genomic Analysis ofInternational journal of microbiology · 2026
    Article
  13. Article
  14. Antimicrobial Resistance Profiles ofPolish journal of microbiology · 2025
    Article
  15. Article
  16. Article
  17. Epidemiological Trends of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Dalal Hammoudi HalatDepartment of Pharmaceutical Sciences, School of Pharmacy, Lebanese International University, Beirut and Bekaa Campuses, Lebanon.
Carole Ayoub MoubareckCollege of Natural and Health Sciences, Zayed University, Dubai, United Arab Emirates.
Lebanese International University · LBZayed University · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Worldwide,

Indexed as

Genetic ProfilePseudomonas aeruginosaAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemscarbapenemasesepidemiologyPseudomonas aeruginosaresistance

Identifiers

PMID36568831
PMCPMC9765337
OpenAlexW4312210457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.